Biologically active substances 'offer range of benefits'
Feb 18 2011
Six separate papers have been published following studies conducted at the Institut de recherches cliniques de Montreal (IRCM), all focusing on a group of PCSK enzymes.
PCSK9 - a Proprotein Convertase, Subtilisin/Kexin enzyme - is of particular interest for research relating to potential health benefits in humans.
The IRCM team, led by Dr Nabil G Seidah, the institute's Biochemical Neuroendocrinology research unit director, linked it with limited generation of fat and maintenance of high levels of circulating cholesterol.
Meanwhile, other biologically active substances in the PCSK family were found to interact with PCSK9, cutting and inactivating it.
Learning more about these processes could lead to therapies for viruses, cancer, neuroendocrine disorders and cardiovascular disease.
The IRCM is about to celebrate its 60th anniversary, having been devised in 1951 by Jacques Genest and set up formally the following year.
In This Edition Modern & Practocal Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...
View all digital editions
Oct 10 2023 Hybrid event
Oct 15 2023 Katowice, Poland
Nov 05 2023 Vienna, Austria
Nov 12 2023 Louisville, KY, USA
Nov 13 2023 Plainsboro, NJ, USA